In silico assessment of plant L-asparaginase and estimating its allergenicity in comparison to bacteria asparaginase

Autor: Maryam Kolahi, Ali Mohamad Foroghmand, Mohammad Reza Tabandeh, Milad Yazdi
Rok vydání: 2020
Předmět:
Zdroj: Pediatric Hematology/Oncology and Immunopathology. 19:35-46
ISSN: 2414-9314
1726-1708
DOI: 10.24287/1726-1708-2020-19-1-35-46
Popis: L-asparaginase is widely distributed among microorganisms, animals and plants. L-asparaginase has been utilized as a drug in the treatment of lymphoid malignancies and plays a crucial role in asparagine metabolism in plant stress response mechanisms. Multiple sequence alignment of Neighbor–Joining phylogenetic tree was executed utilizing Mega 4.0. Two plants asparaginase were identified whose three dimensional structures compared well with two bacterial samples of L-asparaginase used in humans as a therapeutic drug. Prediction of antigen cites, B-cell epitope identification and prediction of epitopes by use of Cytotoxic T-lymphocyte was performed using various in silico server resources. The survey showed that between the 40 plants, 2 identified items of human, 12 bacteria and 6 algae of asparaginase genes, generally two main branches created that samples of green algae is in the neighborhood of to the bacterial samples. Interestingly the data showed that the two bacterial samples of L-asparaginase used in medicine, when compared to plant asparaginase genes, have less similarity to asparaginase genes of human, while the two human asparaginase genes are located perfectly between the plant groups with their sequence revealing high similarity with plant species. Although there was some allergen epitope found in plant asparaginase, these are different from the allergen epitopes of microbial asparaginase that are used as a drug in humans with no common sequence being found between them. This manuscript provides evidence suggesting the potential utilization of Phaseolus vulgaris asparaginase, which has less epitopes, better predicting tool scores and high similarity, in drug design as an enzymetherapy in leukemia and other cancers.
Databáze: OpenAIRE